Time line on HIV/AIDS treatment advances over the past 25 years
1981
CDC reports a new pneumonia, Pneumocystis carinii, in five gay men, later determined to be the first cases of AIDS
1983
First recommendations made for preventing transmission of HIV through sexual contact and blood transfusions
1985
First International AIDS Conference held in Atlanta, Ga.
1986
Zidovudine (AZT) begins clinical trials as first drug to treat AIDS; Surgeon General calls for education and condom use; clean syringe distribution program begins in Boston and New Haven, Conn.
1987
AZT approved by the FDA; FDA creates new class of experimental drugs, Investigational New Drugs, which accelerates drug approval by two to three years
1988
International AIDS Society forms
1990
FDA approves AZT for pediatric AIDS
1991
CDC recommends restrictions on the practice of HIV-positive healthcare workers
1992
First clinical trials of combination therapies; FDA licenses first rapid HIV test
1994
U.S. Public Health Service recommends use of AZT by pregnant women
1995
First PI, saquinavir (Fortovase, Roche), approved in record time by FDA beginning new era of highly active antiretroviral therapy
1996
First NNRTI, nevirapine (Viramune, Boehringer Ingelheim), is approved; first viral load test approved; first HIV urine test approved; drug "cocktails" beginpatients take as many as 60 pills per day
1998
Clinical trials begin for vaccine, AIDSVAX; HHS issues first national guidelines for use of antiretroviral therapy in adults
2000
UNAIDS, WHO negotiate reduced drug prices with pharmaceutical manufacturers for use in developing countries
2001
Generic drug manufacturers offer to produce discounted drugs for developing countries
2002
Approval of Oraquick Rapid HIV1 antibody test-first test to use finger prick
2003
President Bush announces PEPFAR, President's Emergency Plan for AIDS Relief, providing aid to other countries
2004
First saliva-based HIV test approved
2005
AZT's patent expires and FDA approves several generic versions
2006
First single-pill, once-daily, triple-drug combination treatment approved (Atripla)
Return to Drugtopics.com homepage
Related Content
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021Article
A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
